OncoGenetics Fusion Panel
Definition
RNA-based NGS fusion panels screen for known and novel breakpoints in genes such as ALK, ROS1, RET, NTRK1/2/3, FGFR1-3 and MET; these fusions determine response to tyrosine kinase inhibitor therapy, particularly in NSCLC. In validation studies, concordance rates with other methods are 97% for ALK and 95% for ROS1.
Gene/region examined
ALK, BRAF, BRD4, CLIP4, EGFR, ERG, ETV1, ETV4, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, MET, MYB, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, RET, ROS1, TERT, TFE3
Method
Next Generation Sequencing
Accepted sample types
Solid Tumor-FFPE
Description
75 fusion analyses across 26 gene regions.
Inheritance
Detects somatic gene fusions acquired in tumor tissue (arising from chromosomal rearrangement).